ArticleScientific reports2025
Development of a novel quantitative lateral flow assay for vancomycin for therapeutic drug monitoring.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The evolution of next-generation lateral flow assays for bacterial and fungal diagnostics.Mikrochimica acta · 2026Review
- Smartphone-integrated lateral flow assay for robust detection of Δ9-Tetrahydrocannabinol.Biosensors & bioelectronics · 2026Article
- Next-generation hybrid bioanalytical platforms and clinical integration of TDM technologies for precision monitoring to optimize last-resort antibiotic therapy.Frontiers in pharmacology · 2026Review
- 3D Nanofibrous Scaffolds for Encapsulation-Controlled Vancomycin Delivery: Antibacterial Performance and Cytocompatibility.Polymers · 2025Article
- Quantitative Lateral Flow Assay for Meropenem Determination: A Proof-of-Concept Study.ACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antibiotic optimisation through therapeutic drug monitoring (TDM) is a key strategy in tackling antimicrobial resistance. However, current quantification methods rely on laboratory-based equipment, delaying timely dose adjustments. We developed a novel point-of-care lateral flow assay (LFA) for the quantification of vancomycin in serum. Unlike conventional LFAs with a single test and control line, this assay incorporates two test lines: one for vancomycin binding and one for avidin capture of excess conjugate. Gold nanoparticles were conjugated to biotinylated bovine serum albumin-vancomycin, enabling competitive binding with anti-vancomycin antibodies and avidin capture. Signal ratios from smartphone-acquired images were quantified using an automated image analysis algorithm. Applied to vancomycin in serum, the LFA demonstrated a quantitative detection range of 2.88 to 45,000 ng/mL, with good accuracy, reproducibility, and high recovery in spiked samples. This approach offers a promising solution for decentralised, rapid TDM in clinical settings, especially where timely dose optimisation is critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.